CD8A and neoplasm: In conclusion, in this study, we uncovered the ability of APR-246, and potentially cysteine-binding agents in general, to improve the otherwise weak immunogenicity of tumor cells leading to enhanced priming of antigen-specific CD8+ T cells in the TME.